What Arbutus Needs for a Sea Change
Research - It was just over one year ago that Tekmira Pharmaceuticals (TKMR) changed its name to Arbutus Biopharma (ABUS), and its focus to HBV, moving away from … Continue Reading
Read NowResearch
Clearly, SRSE is Sage’s Biggest Event
Research - Shares of Sage Therapeutics (SAGE) fell today on news that data from STATUS — the company’s phase 3 study of SAGE-547 in SRSE – would … Continue Reading
Premium: Read Now
A Matter of Supply and Demand
Research - Ionis (IONS) gained about $1.2 billion in market value this week when a phase 3 study of nusinersen, the company’s antisense drug for Spinal Muscular … Continue Reading
Premium: Read Now
What UniQure Needs for a Sea Change
Research - We’ve been discussing the potential for biotech to play some catchup to the broader market in our monthly webinars of late, and the move is … Continue Reading
Premium: Read Now
It May Not Be Too Late To Participate in a Medivation Deal
Research - A last-minute trade idea for this slow Friday afternoon. As most healthcare investors will be aware, Sanofi (SNY) has made public their desire to purchase … Continue Reading
Premium: Read Now
Catch July’s ‘Healthcare Huddle’ Webinar
Research - On Thursday evening we hosted our monthly ‘Healthcare Huddle’ webinar. We discussed: The state of the markets (why we’re cautiously bullish about equities) The state … Continue Reading
Premium: Read Now
For The Trial, Sage’s Depression Results Couldn’t Be Better
Research - Sage Therapeutics’s (SAGE) Postpartum Depression results are stellar. Even with a smaller sample size (21 patients as opposed to an enrollment goal of 32), SAGE-547 … Continue Reading
Premium: Read Now